Novartis data at ESC Congress 2026 reinforce cardiovascular
Late-breaking Phase IV VICTORION-CHALLENGE data will evaluate Leqvio® (inclisiran) vs. bempedoic acid in achieving LDL-C goalsNew AZALEA-TIMI 71…
New PSMAddition data show 58% lower risk of PSA progression with Pluvicto® in metastatic hormone-sensitive prostate cancer
More durable, deeper PSA response in patients treated with Pluvicto plus standard of care (ARPI + ADT) vs.…
Novartis Fabhalta® (iptacopan) receives FDA traditional
Fabhalta slowed eGFR decline by 48% vs placebo over two years, demonstrating kidney function preservation1 Clinically meaningful improvements of…
The Future of Autoimmune Disease: A Q&A You Need to Read
We sat down with Christy Siegel, SVP and Therapeutic Area Head, Immunology, Novartis US, to explore how the…
Novartis delpacibart braxlosiran (del-brax) Phase I/II
Ad hoc announcement pursuant to Art. 53 LR FORTITUDE study met primary and key secondary endpoints of reduction…
Novartis advances RLT innovation and reinforces leadership
Pluvicto® PSMAddition oral presentation to highlight efficacy outcomes by disease volume and de novo/recurrent metastatic hormone-sensitive prostate cancerKisqali®…
NIPER Mohali and Novartis Partner to Accelerate Pharma Innovation and Academic Research
In a major push to strengthen India’s pharmaceutical innovation ecosystem, the National Institute of Pharmaceutical Education and…
Novartis breaks ground on new global Biomedical Research center in San Diego to accelerate drug discovery
New facility will enable end‑to‑end discovery across key disease areas and technology platforms, joining existing global research sites…
Novartis to build new radioligand therapy site in Denton, Texas, delivering more next‑generation treatments to patients
Facility expected to be operational in 2028 in Dallas-Fort Worth area, expanding largest RLT manufacturing network in USSite…
Novartis to build new radioligand therapy site in Denton, Texas, delivering more next‑generation treatments to patients
Facility expected to be operational in 2028 in Dallas-Fort Worth area, expanding largest RLT manufacturing network in USSite…
New real‑world data reinforce earlier use of Pluvicto™ before chemotherapy in metastatic castration-resistant prostate cancer
In the real-world, Pluvicto™ showed 13.5 months median PFS in chemo-naïve patients with PSMA-positive mCRPCReal‑world evidence showed Pluvicto…
Novartis Leqvio® shows statistically significant and clinically meaningful early LDL-C goal achievement with less muscle pain
V-DIFFERENCE is first study to show that Leqvio prioritized after statins helps more patients achieve guideline low-density lipoprotein…